Eisai begins Phase III breast cancer study

US subsidiary of Japan-based Eisai has initiated a large, randomised Phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate injection to standard weekly paclitaxel as a first or second- line treatment for HER2-negative …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news